Get the Stockscreener App
3.6608
6.85%
-0.2692
After Hours:
3.77
0.1092
+2.98%
Titan Pharmaceuticals Inc De stock is traded at $3.6608, with a volume of 5,725.
It is down -6.85% in the last 24 hours and down -9.61% over the past month.
Titan Pharmaceuticals Inc is a development stage company developing proprietary therapeutics with utilizing ProNeura long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
See More
Previous Close:
$3.93
Open:
$3.85
24h Volume:
5,725
Relative Volume:
0.15
Market Cap:
$3.35M
Revenue:
$61,000
Net Income/Loss:
$-5.46M
P/E Ratio:
-0.5598
EPS:
-6.54
Net Cash Flow:
$-6.76M
1W Performance:
-0.52%
1M Performance:
-9.61%
6M Performance:
-30.93%
1Y Performance:
-46.87%
1-Day Range:
$3.59
$3.85
1-Week Range:
$3.48
$4.1481
52-Week Range:
$3.03
$14.80
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Name
Titan Pharmaceuticals Inc De
Sector
Industry
Phone
(650) 244-4990
Address
400 OYSTER POINT BLVD, SAN FRANCISCO
Compare TTNP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
3.6608 | 3.35M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-19 | Initiated | Maxim Group | Buy |
| Nov-10-17 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Stock (TTNP) Latest News
Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan
NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan
$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan
Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan
Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan
Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan
Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - Stock Titan
Endo's $99M Strategic Sale: International Pharma Division Goes to Knight Therapeutics - Stock Titan
Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan
Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan
Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan
Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan
How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan
Will Amphastar Reveal New Strategic Insights at Upcoming Barclays Healthcare Conference? - Stock Titan
Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan
Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan
Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - Stock Titan
Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - StockTitan
Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan
Adial's Addiction Treatment Clears Critical FDA Hurdle Ahead of 2025 Phase 3 Trials - Stock Titan
Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - Stock Titan
Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan
Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan
Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan
Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan
Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan
Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan
Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - Stock Titan
Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - Stock Titan
Elite Pharmaceuticals (ELTP) Earnings Preview: Q3 Performance & Strategic Roadmap Unveiling Feb 14 - StockTitan
Opioid Use Disorders Market to Reach USD 8.8 Billion by - GlobeNewswire
Critical Safety Signal Emerges: Pliant's IPF Drug Trial Faces Unexpected DSMB Intervention - StockTitan
Breakthrough NPC1 Treatment Data: 87% of Young Patients Show Recovery Signs in Cyclo Trial - StockTitan
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
TFF Pharmaceuticals to Exit Nasdaq: Complete Liquidation Plan Leaves Shareholders in Limbo - StockTitan
Major Biotech Conferences Alert: NRx Pharmaceuticals Sets Stage for Key Industry Updates - StockTitan
Oncology & Obesity Pipeline Update: Terns Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan
Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan
KalVista Pharmaceutical's Major Talent Push: 261,000 Stock Options Awarded in Strategic Growth Move - StockTitan
Cumberland's DMD Heart Disease Drug Shows Breakthrough 5.4% LVEF Improvement in Phase 2 | CPIX Stock News - Stock Titan
Nasdaq Delisting Drama: Universe Pharmaceuticals Given 7 Days to Save Its Listing - StockTitan
X4 Pharma's Latest Employee Stock Plan: Strategic Move to Attract Top Talent - StockTitan
Mental Health Revolution: HOPE's $27M Backed Ketamine Clinic Network Takes Shape With BTIG Partnership - StockTitan
Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan
Major Setback: CARGO's Cancer Treatment Shows Alarming Safety Issues, Forces Company Restructure - StockTitan
Virpax Secures Critical $6M Funding: Game-Changing Move for Probudur Development - StockTitan
Revolutionary Mental Health Company Plans 100M Revenue Push with Ketamine Clinics - StockTitan
Titan Pharmaceuticals Inc De Stock (TTNP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):